245 related articles for article (PubMed ID: 19829059)
1. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.
Kim TJ; Landen CN; Lin YG; Mangala LS; Lu C; Nick AM; Stone RL; Merritt WM; Armaiz-Pena G; Jennings NB; Coleman RL; Tice DA; Sood AK
Cancer Biol Ther; 2009 Dec; 8(23):2263-72. PubMed ID: 19829059
[TBL] [Abstract][Full Text] [Related]
2. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer.
Landen CN; Kim TJ; Lin YG; Merritt WM; Kamat AA; Han LY; Spannuth WA; Nick AM; Jennnings NB; Kinch MS; Tice D; Sood AK
Neoplasia; 2008 Nov; 10(11):1259-67. PubMed ID: 18953435
[TBL] [Abstract][Full Text] [Related]
3. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
Lu C; Shahzad MM; Moreno-Smith M; Lin YG; Jennings NB; Allen JK; Landen CN; Mangala LS; Armaiz-Pena GN; Schmandt R; Nick AM; Stone RL; Jaffe RB; Coleman RL; Sood AK
Cancer Biol Ther; 2010 Feb; 9(3):176-82. PubMed ID: 20009575
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
5. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.
Shao M; Hollar S; Chambliss D; Schmitt J; Emerson R; Chelladurai B; Perkins S; Ivan M; Matei D
Mol Cancer Ther; 2012 Jul; 11(7):1576-86. PubMed ID: 22700681
[TBL] [Abstract][Full Text] [Related]
6. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
Previs RA; Armaiz-Pena GN; Ivan C; Dalton HJ; Rupaimoole R; Hansen JM; Lyons Y; Huang J; Haemmerle M; Wagner MJ; Gharpure KM; Nagaraja AS; Filant J; McGuire MH; Noh K; Dorniak PL; Linesch SL; Mangala LS; Pradeep S; Wu SY; Sood AK
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376174
[TBL] [Abstract][Full Text] [Related]
7. Leukemia regression by vascular disruption and antiangiogenic therapy.
Madlambayan GJ; Meacham AM; Hosaka K; Mir S; Jorgensen M; Scott EW; Siemann DW; Cogle CR
Blood; 2010 Sep; 116(9):1539-47. PubMed ID: 20472832
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Dhillon S
BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
[TBL] [Abstract][Full Text] [Related]
9. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
Previs RA; Armaiz-Pena GN; Lin YG; Davis AN; Pradeep S; Dalton HJ; Hansen JM; Merritt WM; Nick AM; Langley RR; Coleman RL; Sood AK
Mol Cancer Ther; 2015 Dec; 14(12):2677-86. PubMed ID: 26516159
[TBL] [Abstract][Full Text] [Related]
10. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel.
Tedjarati S; Baker CH; Apte S; Huang S; Wolf JK; Killion JJ; Fidler IJ
Clin Cancer Res; 2002 Jul; 8(7):2413-22. PubMed ID: 12114447
[TBL] [Abstract][Full Text] [Related]
11. Estrous cycle modulates ovarian carcinoma growth.
Armaiz-Pena GN; Mangala LS; Spannuth WA; Lin YG; Jennings NB; Nick AM; Langley RR; Schmandt R; Lutgendorf SK; Cole SW; Sood AK
Clin Cancer Res; 2009 May; 15(9):2971-8. PubMed ID: 19383821
[TBL] [Abstract][Full Text] [Related]
12. Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy.
Volk-Draper LD; Rajput S; Hall KL; Wilber A; Ran S
Neoplasia; 2012 Oct; 14(10):926-42. PubMed ID: 23097627
[TBL] [Abstract][Full Text] [Related]
13. Combined treatment strategies for microtubule stabilizing agent-resistant tumors.
Broggini-Tenzer A; Sharma A; Nytko KJ; Bender S; Vuong V; Orlowski K; Hug D; O'Reilly T; Pruschy M
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25694444
[TBL] [Abstract][Full Text] [Related]
14. The promise of antiangiogenic therapy for ovarian cancer.
Jazaeri AA; Slack-Davis JK
Cancer Biol Ther; 2009 Dec; 8(23):2273-4. PubMed ID: 19907207
[No Abstract] [Full Text] [Related]
15. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
[TBL] [Abstract][Full Text] [Related]
16. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
17. MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells.
Chetty C; Lakka SS; Bhoopathi P; Rao JS
Int J Cancer; 2010 Sep; 127(5):1081-95. PubMed ID: 20027628
[TBL] [Abstract][Full Text] [Related]
18. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.
Merritt WM; Lin YG; Spannuth WA; Fletcher MS; Kamat AA; Han LY; Landen CN; Jennings N; De Geest K; Langley RR; Villares G; Sanguino A; Lutgendorf SK; Lopez-Berestein G; Bar-Eli MM; Sood AK
J Natl Cancer Inst; 2008 Mar; 100(5):359-72. PubMed ID: 18314475
[TBL] [Abstract][Full Text] [Related]
19. Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy.
Volk LD; Flister MJ; Bivens CM; Stutzman A; Desai N; Trieu V; Ran S
Neoplasia; 2008 Jun; 10(6):613-23. PubMed ID: 18516298
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
